神经退行性疾病:转化药物发现的病原和临床前模型
Laura Fusaro1, Dinesh S Bangari2, R Jeroen Pasterkamp3
1Denali Therapeutics, South San Francisco, California, USA.
Toxicologic pathology
|May 15, 2025
概括
研究人员探索了神经退行性疾病的体外和体内模型,如痴呆症和ALS. 模拟和大麻素疗法的进步显示了神经保护和神经修复的前景.
科学领域:
- 毒理学病理学 毒理学病理学
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
背景情况:
- 神经退行性疾病在理解病原和开发治疗方法方面带来了重大挑战.
- 目前的研究重点是先进的体外和体内模型来研究复杂的神经疾病.
- 欧洲毒理病理学会 (ESTP) 大会强调了该领域最近的进展.
研究的目的:
- 审查关于神经退行性疾病的体外和体内模型的最新研究.
- 讨论这些模型在研究痴呆症,免疫介导和神经肌肉疾病中的应用.
- 探索新的治疗策略,包括基于大麻素的选择,用于神经退行性疾病.
主要方法:
- 关于痴呆症研究中的动物模型的概述.
- 在自身免疫性神经退行性疾病中对免疫性自我耐受性的研究.
- 在体外模型的应用用于研究神经肌肉疾病,如肌缩性侧面硬化症.
- 检查基于大麻素的治疗方法.
主要成果:
- 动物模型对于理解痴呆病原和药物开发至关重要.
- 研究了自身免疫性神经退行性疾病 (如多发性硬化症,吉兰-巴雷综合征) 的免疫学方面.
- 试验室模型在研究神经肌肉疾病 (例如,肌缩性侧面硬化症) 中具有实用性.
- 基于大麻素的疗法显示出神经保护和神经修复的潜力.
结论:
- 该会议提供了有关当前研究和神经退行性疾病建模方面的进展的宝贵见解.
- 建模方面的进展为改善治疗策略提供了有希望的方向.
- 进一步研究新的治疗选择,如大麻素是有必要的.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.5K
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.2K
相关概念视频
01:28Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28